AU Patent

AU2016205361B2 — Methods of treating conditions related to the S1P1 receptor

Assigned to Arena Pharmaceuticals Inc · Expires 2020-10-15 · 6y expired

What this patent protects

Provided are methods of treatment of a sphingosine 1-phosphate subtype 1 (S1P

USPTO Abstract

Provided are methods of treatment of a sphingosine 1-phosphate subtype 1 (S1P

Drugs covered by this patent

Velsipity (Etrasimod Arginine) · Pfizer Inc.

Patent Metadata

Patent number: AU2016205361B2
Jurisdiction: AU
Classification: —
Expires: 2020-10-15
Drug substance claim: No
Drug product claim: No
Assignee: Arena Pharmaceuticals Inc
Source: FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.